Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579096 · ClinicalTrials.gov registry record · Phase 4
CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 950
- Enrollment target
NCT02579096: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT02579096 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 950 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02579096, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 950 participants
- Enrollment target
Study Summary
This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attacks. These therapies have never been compared at appropriate doses. Further, they will be studied in patients with kidney disease for the first time.
Primary Outcome
Participants were defined as flaring in Phase 3 if they: -1) met 3 of 4 following participant-reported criteria: * a) warm joint(s) * b) swollen joint(s) * c) pain (\>3) at rest on a scale of 0-10 (10 being the worst pain) * d) self-identified gout flare OR -2) reported use of medications to treat flare
Interventions
- DRUG allopurinol capsule, 100-800 mg by mouth once daily
- DRUG febuxostat tablet 40-120 mg by mouth once daily
- DRUG Placebo, vehicle control (febuxostat-shaped)
- DRUG Placebo, vehicle control (allopurinol-shaped)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2021-04-15 |
| Phase | Phase 4 |
What the finished NCT02579096 record still lists
NCT02579096 is an interventional study that assigns participants to a tested intervention. The registered 950 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% higher).
The record links to 0 conditions, and to 4 interventions - of which allopurinol capsule, 100-800 mg by mouth once daily is the first listed.
NCT02579096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02579096 about?
NCT02579096 is a clinical study titled "CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat". This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attacks. These therapies have never been compared at appropriate doses. Further, they will be studied in patients with kidney disease for the first time.
What is the current status of trial NCT02579096?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 950 participants. The study started on 2017-03-06. Estimated completion is 2021-04-15.
What interventions are being tested in trial NCT02579096?
The interventions under investigation include: allopurinol capsule, 100-800 mg by mouth once daily (DRUG), febuxostat tablet 40-120 mg by mouth once daily (DRUG), Placebo, vehicle control (febuxostat-shaped) (DRUG), Placebo, vehicle control (allopurinol-shaped) (DRUG).
Who is sponsoring clinical trial NCT02579096?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02579096's enrollment target sits among peer trials
950 77th of 2000 higher than 1,923 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI